Journal of Oral and Maxillofacial Surgery
Volume 67, Issue 12 , Pages 2644-2648 , December 2009

Correlation Between Serum C-Terminal Cross-Linking Telopeptide of Type I Collagen and Staging of Oral Bisphosphonate-Related Osteonecrosis of the Jaws

  • Yong-Dae Kwon, DMD, MSD, PhD

      Affiliations

    • Assistant Professor, Department of Oral and Maxillofacial Surgery, Institute of Oral Biology, Kyung Hee University Medical Center, Seoul, Korea
    • Corresponding Author InformationAddress correspondence and reprint requests to Dr Kwon: Department of Oral and Maxillofacial Surgery, Kyung Hee University Medical Center, Seoul 130-702 Republic of Korea
    • ,
  • Deog-Yoon Kim, MD, PhD

      Affiliations

    • Professor and Chairman, Department of Nuclear Medicine, Kyung Hee University Medical Center, Seoul, Korea
    • ,
  • Joo-Young Ohe, DMD

      Affiliations

    • Resident, Department of Oral and Maxillofacial Surgery, Institute of Oral Biology, Kyung Hee University Medical Center, Seoul, Korea
    • ,
  • Ji-Yeon Yoo, DMD

      Affiliations

    • Resident, Department of Oral and Maxillofacial Surgery, Institute of Oral Biology, Kyung Hee University Medical Center, Seoul, Korea
    • ,
  • Christian Walter, MD, DDS

      Affiliations

    • Assistant Professor, Department of Oral and Maxillofacial Surgery, University Hospital of Mainz, Mainz, Germany

References 

  1. Ruggiero SL, Mehrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg. 2004;62:527
  2. Dimopoulos MA, Kastritis E, Anagnostopoulos A, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: Evidence of increased risk after treatment with zoledronic acid. Haematologica. 2006;91:968
  3. American Association of Oral and Maxillofacial Surgeons. Position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007;65:369
  4. Rosen HN, Moses AC, Garber J, et al. Serum CTX: A new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int. 2000;66:100
  5. Marx RE, Cillo JE, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007;65:2397
  6. Marx RE. Oral and Intravenous Bisphosphonate-Induced Osteonecrosis of the Jaws. Miami, FL: Quintessence; 2007;
  7. Marx RE, Sawatari Y, Fortin M, et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005;63:1567
  8. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol. 2005;23:8580
  9. Sarasquete ME, Garcia-Sanz R, Marin L, et al. Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: A genome-wide single nucleotide polymorphism analysis. Blood. 2008;112:2709
  10. Kwon Y-D, Yoon B-W, Walter C. Bisphosphonate, is it an emerging risk factor in oral surgery?. J Korean Assoc Maxillofac Plast Reconstr Surg. 2007;29:456
  11. Kwon Y-D, Kim Y-R, Choi B-J, et al. Oral bisphosphonate related osteonecrosis of the jaws: Favorable outcome afterbisphosphonate holiday. Quintessence Int. 2009;40:277
  12. Lenz JH, Steiner-Krammer B, Schmidt W, et al. Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates?. J Cranio-Maxillofacial Surg. 2005;33:395
  13. Hess LM, Jeter JM, Benham-Hutchins M, et al. Factors associated with osteonecrosis of the jaw among bisphosphonate users. Am J Med. 2008;121:475
  14. Altundag K, Bulut N, Tezcan E, et al. Tooth extraction: Is it inciting event or sequela of osteonecrosis of the jaws associated with intravenous bisphosphonates?. J Oral Maxillofac Surg. 2007;65:154
  15. Bisdas S, Chambron Pinho N, Smolarz A, et al. Biphosphonate-induced osteonecrosis of the jaws: CT and MRI spectrum of findings in 32 patients. Clin Radiol. 2008;63:71
  16. Fink E, Cormier C, Steinmetz P, et al. Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy. Osteoporos Int. 2000;11:295
  17. Schwartz HC. Serum CTX testing. J Oral Maxillofac Surg. 2008;66:1319
  18. Khosla S, Burr D, Cauley J, et al. Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2008;66:1320
  19. Bagan JV, Jimenez Y, Gomez D, et al. Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates. Oral Oncol. 2008;44:1088
  20. Kwon Y-D, Kim D-Y. Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates. Oral Oncol. 2009;45:839
  21. Assael LA. Serum CTX to prevent osteonecrosis/orthodontic extraction of third molars: Paths toward minimizing surgical risk?. J Oral Maxillofac Surg. 2007;65:2395
  22. Russell RG, Watts NB, Ebetino FH, et al. Mechanisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008;19:733
  23. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809
  24. Grbic JT, Landesberg R, Lin SQ, et al. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc. 2008;139:32
  25. Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350:1189
  26. Lin JH, Russell G, Gertz B. Pharmacokinetics of alendronate: An overview. Int J Clin Pract Suppl. 1999;101:18

 This research was supported by the Program of Kyung Hee University for the Young Researcher of Medical Science in 2008 (grant 20081267).

PII: S0278-2391(09)00567-9

doi: 10.1016/j.joms.2009.04.067

Journal of Oral and Maxillofacial Surgery
Volume 67, Issue 12 , Pages 2644-2648 , December 2009

Article Tools